{
    "organizations": [],
    "uuid": "72d94a6bb907610f2772209c77b0c685f292a231",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/01/globe-newswire-aeterna-zentaris-to-announce-first-quarter-2018-financial-and-operating-results-on-may-7-2018.html",
    "ord_in_thread": 0,
    "title": "Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CHARLESTON, S.C., May 01, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The Company will host a conference call to discuss these results on Tuesday, May 8, 2018 at 8:30 a.m. Eastern Time.\nParticipants may access the conference call by telephone using the following numbers:\nToll-Free: 877-407-8029, Confirmation #13679691 Toll: 201-689-8029, Confirmation #13679691\nA replay will also be available on the Company’s website for a period of 30 days.\nAbout Aeterna Zentaris Inc.\nAeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com .\nContact:\nAeterna Zentaris Inc.\nJames Clavijo\nChief Financial Officer\nIR@aezsinc.com\n843-900-3201\nSource:Aeterna Zentaris Inc.",
    "published": "2018-05-02T01:05:00.000+03:00",
    "crawled": "2018-05-02T02:19:13.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "charleston",
        "may",
        "globe",
        "newswire",
        "aeterna",
        "zentaris",
        "nasdaq",
        "aezs",
        "tsx",
        "aezs",
        "announce",
        "first",
        "quarter",
        "financial",
        "operating",
        "result",
        "market",
        "close",
        "monday",
        "may",
        "company",
        "host",
        "conference",
        "call",
        "discus",
        "result",
        "tuesday",
        "may",
        "eastern",
        "time",
        "participant",
        "may",
        "access",
        "conference",
        "call",
        "telephone",
        "using",
        "following",
        "number",
        "confirmation",
        "toll",
        "confirmation",
        "replay",
        "also",
        "available",
        "company",
        "website",
        "period",
        "day",
        "aeterna",
        "zentaris",
        "aeterna",
        "zentaris",
        "specialty",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "commercializing",
        "principally",
        "arrangement",
        "macimorelin",
        "orally",
        "available",
        "ghrelin",
        "agonist",
        "used",
        "diagnosis",
        "patient",
        "adult",
        "growth",
        "hormone",
        "deficiency",
        "aeterna",
        "zentaris",
        "entered",
        "license",
        "assignment",
        "agreement",
        "subsidiary",
        "strongbridge",
        "biopharma",
        "plc",
        "carry",
        "development",
        "manufacturing",
        "registration",
        "commercialization",
        "macimorelin",
        "united",
        "state",
        "canada",
        "information",
        "visit",
        "contact",
        "aeterna",
        "zentaris",
        "james",
        "clavijo",
        "chief",
        "financial",
        "officer",
        "ir",
        "source",
        "aeterna",
        "zentaris",
        "inc"
    ]
}